波生坦治疗特发性肺动脉高压的临床疗效

The clinical efficay of bosentan for idiopathic pulmonary arterial hypertension

目的探讨口服波生坦治疗特发性肺动脉高压（IPAH）的临床效果。方法将45例特发性肺动脉高压患者随机分为治疗组23例和对照组22例；两组均采取常规治疗，治疗组在此基础上口服波生坦；根据观察结果，分析、探讨两组的治疗效果。结果经过14d治疗，治疗组PaO2和6MWD分别为（81．0±3．7）mmHg（1mmHg=0．133kPa）和（331．0±81．2）m，较对照组的（57．0±3．9）mmHg和（263．0±58．9）m高；PaCO2、PAP分别为（43．0±5．9）mmHg和（63．0±17．1）mmHg，较对照组的（66．0±7．2）mmHg和（78．0±16．7）mmHg低；两组比较差异均有显著性（P〈0．05）。结论口服波生坦能有效治疗特发性肺动脉高压，显著降低肺动脉压。

Objective To explore the efficacy of bosentan in the treatment of idiopathic pulmonary arterial hypertension （ IPAH ）. Methods 45 patients with IPAH were randomly assigned to study group （ 23 patients ） or control group （ 22 patients ）. Both groups received conventional therapies and the study group was administered oral bosentan additionally. The efficacy was then analyzed in the two groups. Results 14 days after treatment, levels of PaO2 and 6MWD were higher whereas levels of PaCO2 and PAP were lower in the study group than in the control group [（ 81 ± 3.7 ）mmHg （1mmHg=0.133kPa） vs.（ 57.0± 3.9） mmHgand （331.0±81.2） m vs.（ 263.0 ± 58.9） m, and （43.0 ± 5.9） mmHg vs.（ 66.0 ± 7.2 ）mm Hg and （ 63.0 ± 17.1 ） mm Hg vs.（ 78.0 ± 16.7 ） mm Hg; P 〈 0.05 for all comparisons]. Conclusions Oral bosentan is efficacious in the treatment of idiopathic pulmonary arterial hypertension, significantly reducing high pressure of pulmonary artery.